In vivo animal testing is a cornerstone of biological safety evaluation, delivering critical data on systemic toxicity, sensitization, irritation, implantation response, and pyrogenicity for medical devices, pharmaceuticals, and industrial chemicals. These studies are performed by accredited third-party laboratories in accordance with the ISO 10993 series, OECD test guidelines, and GLP principles to support regulatory submissions across global markets. This article provides a detailed overview of in vivo animal test samples, testing items, methods, standards, and typical applications.
Technical Overview
In vivo animal testing refers to a family of biological safety studies in which a test article, or extracts prepared from it, is administered to live animal models—typically mice, rats, guinea pigs, rabbits, or hamsters—in order to characterize toxicological hazards that cannot yet be fully predicted by in vitro methods alone. Because living systems integrate absorption, distribution, metabolism, excretion, immune responses, and tissue repair, in vivo studies provide essential whole-organism evidence for hazard identification and risk assessment.
For medical devices, in vivo evaluation is required by the ISO 10993 series of standards, which are harmonized in China as the GB/T 16886 series. The standards define which biological endpoints must be addressed based on the nature of body contact (surface, external communication, or implantation) and contact duration (limited, prolonged, or permanent). For chemicals and pharmaceuticals, study designs follow OECD Test Guidelines and ICH safety guidance, with study conduct governed by Good Laboratory Practice (GLP) principles such as the OECD GLP framework and 21 CFR Part 58.
All in vivo programs are executed under institutional animal care and use committee (IACUC) approval and adhere to the 3Rs principle—Replacement, Reduction, and Refinement. This ensures that animal use is scientifically justified, that the number of animals is minimized through appropriate statistical design, and that procedures are refined to minimize pain and distress. Where validated non-animal alternatives exist, such as the monocyte activation test for pyrogenicity or the in vitro sensitization methods of the OECD TG 442 series, they are incorporated into the test strategy in line with regulatory expectations.
Testing Samples
Medical Devices and Biomaterials
Finished devices, device components, representative material coupons, and raw biomaterials intended for patient contact are the most common submissions. Typical categories include:
- Surface-contacting devices: electrodes, adhesive tapes, compression bandages, and fixation devices
- External communication devices: infusion sets, extracorporeal circulation tubing, catheters, endoscopes, and laparoscopic instruments
- Implantable devices: vascular stents, orthopedic prostheses, spinal fixation systems, dental implants, bone cements, and absorbable scaffolds
- Raw biomaterials: polymers, metals and alloys, ceramics, hydrogels, coatings, and tissue-engineering matrices
Extracts and Test Article Preparations
Because most devices cannot be dosed directly, polar and non-polar extracts are prepared according to ISO 10993-12 using standardized surface-area-to-volume or mass-to-volume ratios and controlled extraction conditions. The resulting extracts are used for systemic toxicity, intracutaneous reactivity, sensitization, and pyrogenicity studies.
Pharmaceuticals, Chemicals, and Consumer Products
- Active pharmaceutical ingredients and formulated drug products for preclinical safety evaluation
- Industrial chemicals, intermediates, and agrochemicals evaluated under chemical registration schemes
- Food contact materials and food additives
- Cosmetic ingredients, where animal testing is required or permitted by the applicable jurisdiction
Testing Items
In vivo testing portfolios are tailored to the product category and regulatory endpoint, and typically include the following studies:
- Acute systemic toxicity (ISO 10993-11; OECD TG 423 and TG 425)
- Subacute and subchronic toxicity, including 14-day, 28-day, and 90-day studies (ISO 10993-11; OECD TG 407 and TG 408)
- Chronic toxicity (OECD TG 452)
- Skin sensitization using the Guinea Pig Maximization Test (Magnusson-Kligman method) or the Buehler assay (ISO 10993-10; OECD TG 406)
- Sensitization using the murine Local Lymph Node Assay (OECD TG 429)
- Skin irritation (ISO 10993-23; OECD TG 404)
- Intracutaneous reactivity (ISO 10993-23; USP General Chapter 88)
- Eye irritation, including the Draize test (OECD TG 405)
- Pyrogenicity using the rabbit pyrogen test (ISO 10993-11; pharmacopoeial methods)
- Implantation testing, short-term and long-term, in muscle, subcutaneous tissue, or bone (ISO 10993-6; ASTM F763 and ASTM F981)
- In vivo hemocompatibility and thromboresistance evaluation (ISO 10993-4)
- In vivo genotoxicity, including the rodent micronucleus assay (OECD TG 474) and the comet assay (OECD TG 489)
- Reproductive and developmental toxicity screening (OECD TG 414, TG 421, and TG 422)
- Carcinogenicity testing (OECD TG 451)
- Safety pharmacology core battery studies (ICH S7A)
Testing Methods
Study design begins with device categorization under ISO 10993-1, chemical characterization, and a toxicological risk assessment to justify the test selection matrix. Protocols are then developed to meet the specific endpoint, route of exposure, and applicable regulatory data requirements.
Sample Preparation and Extraction
Extractions are performed per ISO 10993-12 using a polar medium (such as sodium chloride injection), a non-polar medium (such as sesame or vegetable oil), and additional media where warranted. Standard extraction conditions include 37 degrees Celsius for 72 hours, 50 degrees Celsius for 72 hours, 70 degrees Celsius for 24 hours, or 121 degrees Celsius for 1 hour, selected so that extraction is exhaustive yet does not degrade the material. Typical extraction ratios are 3 cm²/mL based on surface area or 0.1 to 0.2 g/mL based on material mass.
Representative Study Designs
- Acute systemic toxicity: a single intravenous or intraperitoneal dose of test extract is administered to mice, with clinical observations at 4, 24, 48, and 72 hours covering mortality, clinical signs, and body weight change.
- Intracutaneous reactivity: polar and non-polar extracts are injected intradermally at multiple sites in rabbits, and erythema, eschar, and edema are scored at 24, 48, and 72 hours to calculate the primary irritation index.
- Guinea Pig Maximization Test: intradermal induction with and without Freund's complete adjuvant is followed by topical induction and challenge; responses graded 0 to 3 are compared with control animals, with sensitization rates of 30 percent or more indicating a sensitizer.
- Buehler assay: repeated topical induction and subsequent topical challenge are applied to guinea pigs, with a 15 percent or greater response rate indicating sensitization.
- Local Lymph Node Assay: proliferative responses in draining lymph nodes of mice are quantified, and a stimulation index of 3 or greater classifies the material as a skin sensitizer.
- Rabbit pyrogen test: test extract is administered intravenously at a defined dose per kilogram of body weight, and temperature responses are recorded over three hours and evaluated against pharmacopoeial limits.
- Implantation studies: test and control implants are placed in paravertebral muscle, subcutaneous tissue, or bone of rabbits or rats, and tissue reactions are compared histopathologically at 1, 4, 12, 26, or more weeks post-implantation.
Data Collection and Reporting
End points typically include clinical observations, body weight, food and water consumption, hematology, coagulation, clinical chemistry, gross necropsy, organ weights, and histopathology. Data are subjected to appropriate statistical analysis, and GLP-compliant final reports are issued with full documentation of protocol deviations, quality assurance audits, and archiving, ensuring acceptance by regulatory reviewers.
Applications
In vivo animal study data support a wide range of regulatory and development objectives:
- Biocompatibility dossiers for medical device registration with national regulators, including submissions for the Chinese market, the United States market, and CE marking under the EU Medical Device Regulation
- Preclinical safety packages enabling investigational new drug and clinical trial applications for pharmaceutical candidates
- Chemical registration dossiers under regional chemical control programs such as REACH
- Material screening, selection, and design verification during research and development
- Root-cause analysis and biological safety re-evaluation following product changes, complaints, or adverse event investigations
- Market access documentation for exporters requiring internationally recognized biocompatibility evidence
FAQ
Which standards govern in vivo animal testing?
For medical devices, the primary framework is the ISO 10993 series, including ISO 10993-1 for test selection, ISO 10993-6 for implantation, ISO 10993-10 for sensitization, ISO 10993-11 for systemic toxicity and pyrogenicity, ISO 10993-12 for sample preparation, and ISO 10993-23 for irritation. In China, the equivalent GB/T 16886 series applies. Chemical and pharmaceutical studies follow OECD Test Guidelines and ICH guidance, with ASTM F719, F720, F750, F1903, and F2148 providing supplementary methods for specific endpoints.
How is animal welfare protected during these studies?
Every study is reviewed and approved by an institutional animal care and use committee before initiation. Laboratories apply the 3Rs principle, use species-appropriate housing and environmental enrichment, apply anesthesia and analgesia where needed, define humane endpoints in advance, and conduct studies under GLP quality systems with documented veterinary oversight.
How long do in vivo studies take?
Acute systemic toxicity studies are typically completed within one to two weeks. Intracutaneous reactivity and irritation studies require one to two weeks, the Local Lymph Node Assay approximately one week, and Guinea pig sensitization assays four to six weeks. Implantation studies range from several weeks to a year or longer, while 90-day subchronic studies include acclimation, dosing, and recovery periods totaling roughly four to five months.
How much sample is required for testing?
Sample requirements depend on the extraction ratio, the number of dose groups, and the specific protocol. Accredited third-party laboratories provide submission checklists specifying the required mass, surface area, or number of finished device units for each study, and representative sampling must follow ISO 10993-12 and relevant statistical rationale.
Can in vitro methods fully replace in vivo animal testing?
Non-animal approaches continue to expand, including the monocyte activation test for pyrogenicity, reconstructed human epidermis models for irritation under ISO 10993-23, and defined in vitro sensitization assays in the OECD TG 442 series. However, for many endpoints and contact categories, regulators still expect in vivo data or a weight-of-evidence justification combining chemical characterization, in vitro results, and existing literature before waiving animal studies.
Are study reports acceptable for international regulatory submissions?
Yes. Studies conducted under GLP in accordance with the OECD GLP principles or 21 CFR Part 58, and performed to ISO 10993, OECD, ASTM, EN, or GB standards as applicable, are accepted by major regulatory authorities worldwide and can be presented as part of a manufacturer's biological evaluation file.